论文部分内容阅读
目的探讨罗格列酮对高血压合并糖耐量减低患者血糖、血压、胰岛素抵抗、血管内皮功能的影响及其氧化应激机制。方法100例高血压合并糖耐量减低(IGT)患者随机分为罗格列酮治疗组(55例)和常规治疗组(45例)。另选取健康体检者作为对照组(45例)。疗程8周,比较治疗前后血压、空腹血糖、胰岛素、胰岛素抵抗指数、一氧化氮、内皮素-1、丙二醛、红细胞超氧化物岐化酶的变化。结果罗格列酮治疗8周后,血压、空腹血糖、胰岛素水平、胰岛素抵抗指数较前明显下降(P<0.05);内皮素-1、丙二醛水平显著降低(P<0.05);一氧化氮、红细胞超氧化物岐化酶水平显著升高(P<0.05)。结论罗格列酮可显著改善高血压并IGT患者的血压、血糖和胰岛素抵抗,其机制可能与降低机体氧化应激,改善内皮功能有关。
Objective To investigate the effects of rosiglitazone on blood glucose, blood pressure, insulin resistance and vascular endothelial function in patients with hypertension and impaired glucose tolerance and its mechanism of oxidative stress. Methods One hundred patients with IGT were randomly divided into rosiglitazone treatment group (n = 55) and conventional treatment group (n = 45). Another health examination as a control group (45 cases). The course of treatment was 8 weeks. The changes of blood pressure, fasting blood glucose, insulin, insulin resistance index, nitric oxide, endothelin - 1, malondialdehyde and erythrocyte superoxide dismutase were compared before and after treatment. Results After 8 weeks treatment with rosiglitazone, the blood pressure, fasting blood glucose, insulin and insulin resistance index decreased significantly (P <0.05), the levels of ET-1 and MDA significantly decreased (P <0.05) Nitrogen and erythrocyte superoxide dismutase levels were significantly increased (P <0.05). Conclusions Rosiglitazone can significantly improve blood pressure, blood glucose and insulin resistance in patients with hypertension and IGT. The mechanism may be related to reducing oxidative stress and improving endothelial function.